Empowering CLL patients: Do physicians need more communication skills training?
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017
Jesús San Miguel
Current and potential PI3K and BTK inhibitors for CLL
What we are learning about CLL treatments and the microenvironment